Shruti Warhadpande

The paper identifies hormone signaling and immune programs as factors determining endocrine responsiveness in breast tissue with background parenchymal enhancement.

EpiBlot maps chromatin accessibility and proteoform expression in HER2-expressing breast cancer cells, revealing distinct epigenetic and protein responses to therapies.

The paper develops predictive models using patient-derived breast cancer organoids to identify drug responses and guide new therapies for resistant disease.

This study shows that fine needle aspiration biopsy (FNAB) effectively harvests cells for patient-derived organoids modeling breast ductal carcinoma in situ, with faster growth times compared to core needle biopsy.